Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: 5G1.1-SC; Anti-C5 monoclonal antibody 5G1-1-SC; h5G1.1-scFV; Monoclonal antibody 5G1.1-SC; Short-acting monoclonal antibody 5G1.1

Latest Information Update: 07 May 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Stanford University
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Complement C5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Myocardial infarction; Reperfusion injury

Most Recent Events

  • 07 May 2007 Proctor & Gamble terminates its licence for pexelizumab worldwide
  • 28 Jun 2006 Interim results from a phase III clinical trial (APEX-AMI) in patients with myocardial infarction have been added to the Ischaemic Heart Disease therapeutic trials section
  • 09 Aug 2005 Alexion Pharmaceuticals and Procter & Gamble have completed enrollment in the PRIMO-CABG2 trial
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top